PDF(Pubmed)
Abstract：
UNASSIGNED: Due to its rarity, there is insufficient evidence for managing ASCC patients with distant metastasis. Thus far, the therapeutic strategy for distant metastasis of ASCC is less standardized and requires a more individualized approach. Therefore, it is crucial to obtain information regarding treatment outcomes and prognostic factors following the development of distant metastasis to identify optimal care strategies for better patient outcomes and predict their prognosis.
UNASSIGNED: In the multi-institute cohort study conducted in Japan, we retrospectively assessed 58 ASCC patients with synchronous distant metastasis and 28 ASCC patients with metachronous distant metastasis.
UNASSIGNED: When comparing the OS between ASCC patients with synchronous distant metastasis and metachronous distant metastasis, there was no statistically significant difference between the two groups. The OS rate at five years was 37.4% for patients with synchronous distant metastasis and 27.6%; for metachronous distant metastasis. In ASCC patients with synchronous distant metastasis, patients with distant metastasis at multiple sites exhibited extremely worse OS than those at single sites (HR: 4.56, 95% CI: 1.16-18.00, P< 0.0001). In addition, in ASCC patients with metachronous distant metastasis, early recurrence was an independent factor for predicting poor OS in the multivariate analysis (HR: 4.13, 95% CI: 1.22-13.94, P = 0.022).
UNASSIGNED: ASCC patients with distant metastasis at multiple sites were a worse prognosis. In addition, early recurrence was identified as an independent prognostic factor for OS among ASCC patients.
UNASSIGNED: In the multi-institute cohort study conducted in Japan, we retrospectively assessed 58 ASCC patients with synchronous distant metastasis and 28 ASCC patients with metachronous distant metastasis.
UNASSIGNED: When comparing the OS between ASCC patients with synchronous distant metastasis and metachronous distant metastasis, there was no statistically significant difference between the two groups. The OS rate at five years was 37.4% for patients with synchronous distant metastasis and 27.6%; for metachronous distant metastasis. In ASCC patients with synchronous distant metastasis, patients with distant metastasis at multiple sites exhibited extremely worse OS than those at single sites (HR: 4.56, 95% CI: 1.16-18.00, P< 0.0001). In addition, in ASCC patients with metachronous distant metastasis, early recurrence was an independent factor for predicting poor OS in the multivariate analysis (HR: 4.13, 95% CI: 1.22-13.94, P = 0.022).
UNASSIGNED: ASCC patients with distant metastasis at multiple sites were a worse prognosis. In addition, early recurrence was identified as an independent prognostic factor for OS among ASCC patients.
摘要：
■由于其稀有性，对于有远处转移的ASCC患者的治疗没有足够的证据.到目前为止,ASCC远处转移的治疗策略不太标准化,需要更加个体化的方法.因此,在远处转移发生后,获取有关治疗结局和预后因素的信息,以确定最佳的治疗策略,从而获得更好的患者结局并预测其预后至关重要.
■在日本进行的多机构队列研究中，我们回顾性评估了58例同时发生远处转移的ASCC患者和28例异时远处转移的ASCC患者。
■当比较有同步远处转移和异时远处转移的ASCC患者的OS时，两组间差异无统计学意义。同步远处转移患者的五年OS率为37.4％，异时远处转移患者为27.6％。在同步远处转移的ASCC患者中，多部位远处转移患者的OS显著低于单部位(HR:4.56,95%CI:1.16~18.00,P<0.0001).此外,在有异时远处转移的ASCC患者中，在多因素分析中,早期复发是预测OS差的独立因素(HR:4.13,95%CI:1.22~13.94,P=0.022).
■有多个部位远处转移的ASCC患者预后较差。此外,在ASCC患者中,早期复发是OS的独立预后因素.
■在日本进行的多机构队列研究中，我们回顾性评估了58例同时发生远处转移的ASCC患者和28例异时远处转移的ASCC患者。
■当比较有同步远处转移和异时远处转移的ASCC患者的OS时，两组间差异无统计学意义。同步远处转移患者的五年OS率为37.4％，异时远处转移患者为27.6％。在同步远处转移的ASCC患者中，多部位远处转移患者的OS显著低于单部位(HR:4.56,95%CI:1.16~18.00,P<0.0001).此外,在有异时远处转移的ASCC患者中，在多因素分析中,早期复发是预测OS差的独立因素(HR:4.13,95%CI:1.22~13.94,P=0.022).
■有多个部位远处转移的ASCC患者预后较差。此外,在ASCC患者中,早期复发是OS的独立预后因素.
